These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 12429617)

  • 21. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
    Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
    Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: usefulness of different quantitative methods of tumor proliferation.
    Marti-Climent JM; Dominguez-Prado I; Garcia-Velloso MJ; Boni V; Peñuelas I; Toledo I; Richter JA
    Rev Esp Med Nucl Imagen Mol; 2014; 33(5):280-5. PubMed ID: 25066253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
    Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
    J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
    Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA
    J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis.
    Shen G; Ma H; Pang F; Ren P; Kuang A
    Acta Radiol; 2018 Feb; 59(2):188-195. PubMed ID: 28475024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.
    Contractor KB; Kenny LM; Stebbing J; Rosso L; Ahmad R; Jacob J; Challapalli A; Turkheimer F; Al-Nahhas A; Sharma R; Coombes RC; Aboagye EO
    Clin Cancer Res; 2011 Dec; 17(24):7664-72. PubMed ID: 22028493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
    J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study.
    Kaira K; Oriuchi N; Otani Y; Shimizu K; Tanaka S; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Dobashi K; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
    Clin Cancer Res; 2007 Nov; 13(21):6369-78. PubMed ID: 17975149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
    Yamane T; Takaoka A; Kita M; Imai Y; Senda M
    Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
    Vesselle H; Salskov A; Turcotte E; Wiens L; Schmidt R; Jordan CD; Vallières E; Wood DE
    J Thorac Oncol; 2008 Sep; 3(9):971-8. PubMed ID: 18758298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival.
    Linecker A; Kermer C; Sulzbacher I; Angelberger P; Kletter K; Dudczak R; Ewers R; Becherer A
    Nuklearmedizin; 2008; 47(2):80-5; quiz N12. PubMed ID: 18392317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.
    Fushiki H; Miyoshi S; Noda A; Murakami Y; Sasaki H; Jitsuoka M; Mitsuoka K; Matsunari I; Nishimura S
    Anticancer Res; 2013 Nov; 33(11):4741-9. PubMed ID: 24222108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients.
    Johnbeck CB; Knigge U; Langer SW; Loft A; Berthelsen AK; Federspiel B; Binderup T; Kjaer A
    J Nucl Med; 2016 Dec; 57(12):1851-1857. PubMed ID: 27469355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo imaging of cell proliferation enables the detection of the extent of experimental rheumatoid arthritis by 3'-deoxy-3'-18f-fluorothymidine and small-animal PET.
    Fuchs K; Kohlhofer U; Quintanilla-Martinez L; Lamparter D; Kötter I; Reischl G; Röcken M; Pichler BJ; Kneilling M
    J Nucl Med; 2013 Jan; 54(1):151-8. PubMed ID: 23213198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
    Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS
    Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3'deoxy-3-fluorothymidine positron emission tomography/computed tomography imaging.
    Richard SD; Bencherif B; Edwards RP; Elishaev E; Krivak TC; Mountz JM; DeLoia JA
    Nucl Med Biol; 2011 May; 38(4):485-91. PubMed ID: 21531285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging proliferation of ¹⁸F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer.
    Yang W; Zhang Y; Fu Z; Sun X; Mu D; Yu J
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1289-96. PubMed ID: 22581165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
    Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
    PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.